ACADIA Pharmaceuticals Inc.  

(Public, NASDAQ:ACAD)   Watch this stock  
Find more results for ACAD
32.30
-0.10 (-0.31%)
Apr 29 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 31.74 - 33.15
52 week 16.64 - 51.99
Open 33.04
Vol / Avg. 2.10M/4.11M
Mkt cap 3.60B
P/E     -
Div/yield     -
EPS -1.63
Shares 112.64M
Beta 3.72
Inst. own 91%
Jun 14, 2016
ACADIA Pharmaceuticals Inc Annual Shareholders Meeting (Estimated) - 11:00AM EDT - Add to calendar
May 5, 2016
Q1 2016 ACADIA Pharmaceuticals Inc Earnings Release (Estimated) - 9:30AM EDT - Add to calendar
Apr 12, 2016
ACADIA Pharmaceuticals Inc at Needham Healthcare Conference - Webcast
Mar 8, 2016
ACADIA Pharmaceuticals Inc at Cowen Health Care Conference - Webcast
Feb 29, 2016
Q4 2015 ACADIA Pharmaceuticals Inc Earnings Release
Feb 29, 2016
Q4 2015 ACADIA Pharmaceuticals Inc Earnings Call - Webcast
Feb 10, 2016
ACADIA Pharmaceuticals Inc at Leerink Partners Global Healthcare Conference - Webcast
More events from DailyFinance »    

Key stats and ratios

Q4 (Dec '15) 2015
Net profit margin -269317.70% -269578.70%
Operating margin -268029.40% -269855.80%
EBITD margin - -268795.10%
Return on average assets -78.61% -60.09%
Return on average equity -85.99% -64.58%
Employees 160 -
CDP Score - -

Address

3611 Valley Centre Dr Ste 300
SAN DIEGO, CA 92130-3331
United States - Map
+1-858-5582871 (Phone)
+1-858-5582872 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

ACADIA Pharmaceuticals Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of medicines for the treatment of neurological and related central nervous system disorders. The Company’s drug candidate NUPLAZID (pimavanserin) is under development for the treatment of Parkinson’s disease psychosis, Alzheimer’s disease psychosis, Schizophrenia and Sleep disturbances. The Company is also conducting preclinical programs for alpha adrenergic agonists indicated for the treatment of chronic pain and muscarinic drugs for the treatment of glaucoma. NUPLAZID has an active ingredient pimavanserin, is a selective serotonin inverse agonist (SSIA) preferentially targeting 5-HT2A receptors that was discovered by the Company. The Company in collaboration with Allergan, has discovered and engaged in the development of small-molecule product candidates, such as alpha adrenergic agonists and muscarinic receptors.

Officers and directors

Leslie L. Iversen Ph.D. Independent Chairman of the Board
Age: 77
Bio & Compensation  - Reuters
Stephen R. Davis President, Chief Executive Officer, Chief Financial Officer, Director
Age: 54
Bio & Compensation  - Reuters
Glenn F. Baity Executive Vice President, General Counsel, Secretary
Age: 45
Bio & Compensation  - Reuters
Terrence O. Moore Executive Vice President, Chief Commercial Officer
Age: 60
Bio & Compensation  - Reuters
Srdjan Stankovic M.D. Executive Vice President, Head - Research and Development
Age: 58
Bio & Compensation  - Reuters
Julian C. Baker Director
Age: 49
Bio & Compensation  - Reuters
James M. Daly Director
Bio & Compensation  - Reuters
Edmund P. Harrigan M.D. Director
Age: 56
Bio & Compensation  - Reuters
Stephen R. Biggar M.D., Ph.D. Independent Director
Age: 44
Bio & Compensation  - Reuters
Laura A. Brege Independent Director
Age: 57
Bio & Compensation  - Reuters